You are here: Industry Insights > Pfenex

News List

Ligand to Acquire Pfenex americanpharmaceuticalreview
August 19, 2020
Ligand Pharmaceuticals and Pfenex announced the signing of a definitive agreement for Ligand to acquire all outstanding shares of Pfenex for $12.00 per share in cash or $438 million in equity value on a fully diluted basis.
Ligand Pharmaceuticals agrees to acquire Pfenex for $516m pharmaceutical-technology
August 12, 2020
Ligand Pharmaceuticals has entered into a definitive agreement to acquire development and licencing biotechnology firm Pfenex in a deal valued at approximately $516m.
Pfenex Announces U.S. Commercial Launch of Teriparatide Injection americanpharmaceuticalreview
June 23, 2020
Pfenex announced its commercialization partner, Alvogen, has launched Teriparatide Injection in the United States.
Pfenex, Arcellx Announce Development, Evaluation and License Agreement contractpharma
August 02, 2019
Arcellx gains access to Pfenex Expression Technology® platform to advance multiple proprietary sparX proteins.
Pfenex Announces New COO contractpharma
September 12, 2018
Dr. Shawn A. Scranton joins the company with two decades of industry experience
Pfenex Earns $18.5M in Milestones and Updates Worldwide License and Option Agreement With Jazz Pharm biospace
December 20, 2017
Pfenex Inc. (NYSE AMERICAN: PFNX) today announced the amendment of the 2016 agreement under which Pfenex granted Jazz Pharmaceuticals worldwide rights to develop and commercialize multiple early stage hematology product candidates.